Her3-Targeted Immunotherapy Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0023
Release Date: On the same day of purchase

Her3-Targeted Immunotherapy Pipeline Review

Target: Her3; human epidermal growth factor receptor 3; ErbB3

Product Category: Antibody;

This product provides basic information on immunotherapeutics in R&D targeting Her3.

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
  • Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for immunotherapeutics targeting Her3 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

HER3 is a member of the epidermal growth factor receptor (ERBB) family of tyrosine kinase receptors. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation.

Her3 is overexpressed in a broad range of tumors and is associated with disease progression and poor survival. For example, more than 50% of melanoma, cervical, lung, gastric, colorectal, and ovarian cancers show overexpression of HER3, while in breast, pancreatic and prostate cancers the overexpression ranges between 25-40%. In addition, recent studies show that HER3 expression is significantly induced in tumors during metastasis (in colorectal) and during acquired resistance to tyrosine kinase inhibitors (TKI) in lung cancers.

This widespread overexpression of HER3 makes it an ideal target for antibody drug conjugates (ADCs) and bispecific antibodies targeting Her3 and a second, co-expressed tumor associated antigen. In addition, these new drug modalities promise improved antitumor activity compared to first generation naked antibodies.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01